RPL34P17

Across TCGA pan-cancer cohorts, RPL34P17 RNA is linked to patient survival in 15 of 34 cancer types, making it the most broadly survival-associated RPL34P17 data layer.

The strongest signal is observed in cholangiocarcinoma (CHOL), where higher RPL34P17 RNA is associated with better disease-free survival. In most high-consensus cancer types, elevated RPL34P17 expression acts as an unfavorable survival marker, although some lineages such as CHOL and LUAD show a favorable association.

CHOL, LUAD, and OV are the cancer types where RPL34P17 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CHOL	DFS	Tertile	II,III,IV	1.000	0.127	.001	57	view →
LUAD	DFS	Tertile	All	0.869	0.767	.007	39	view →
OV	OS	Tertile	IV	0.008	0.760	<.001	36	view →
HNSC	DFS	Tertile	II,III,IV	0.173	0.562	.003	36	view →
MESO	OS	Tertile	IV	0.077	0.592	.019	27	view →
TGCT	DFS	Tertile	III,IV	0.017	0.923	.021	18	view →
READ	OS	Tertile	II,III,IV	1.000	0.356	.018	18	view →
LIHC	DFS	Tertile	All	0.100	0.526	.038	18	view →
ESCA	OS	Quartile	III,IV	0.618	0.322	.031	15	view →
UVM	OS	Tertile	All	0.315	0.711	.049	9	view →
COAD	OS	Tertile	IV	0.222	0.622	.010	9	view →
LGG	DFS	Tertile	All	0.918	0.727	.030	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 15 lineages.

RPL34P17–CHOL (DFS)

Open the CHOL breakdown →